ABSTRACT
Unforeseen toxicity is one of the main reasons for the failure of drug candidates. A reliable screening of drug candidates on toxicological side effects in early stages of the lead component development can help in prioritizing candidates and avoiding the futile use of expensive clinical trials and animal tests. A better understanding of the underlying cause of toxicological and pharmacokinetic responses will be useful to develop such screening procedure (1).
